    Dhiren D'Silva | Avadel Pharmaceuticals Plc | ZoomInfo.com

Dhiren Dsilva - MarketVisual Knowledge Map


































Login


Register


Contact Us


My Recent Reports







                    
New Search:























Dhiren Dsilva




Dhiren Dsilva








            Company Affiliations








                        Company
                    

                        # of Roles
                    








Strides Inc

1
                        






            Current Affiliations

Executive




        VICE PRESIDENT at
        Strides Inc







            Past Affiliations


































Learn how a tech company in India won business in:

North and Latin America
Europe
Asia








        Discover the power of enterprise relationship mapping for strategic sales


            Learn More



Relationship Mapping for Enterprise Sales














                ©2017 — IntellectSpace Corporation. All Rights Reserved.









 ;




Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version















Insider Trading - D'silva Dhiren - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - D'silva Dhiren





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2017-01-03Option Award
2017-01-037:09 pm
N/AN/A
Avadel Pharmaceuticals Plc
AVDL
D'silva DhirenSee Remarks
15,000
$0
80,000(Direct)
View


2017-01-03Option Award
2017-01-037:09 pm
N/A2025-09-15
Avadel Pharmaceuticals Plc
AVDL
D'silva DhirenSee Remarks
50,000
$23.53
80,000(Direct)
View


2017-01-03Option Award
2017-01-037:09 pm
N/A2026-12-14
Avadel Pharmaceuticals Plc
AVDL
D'silva DhirenSee Remarks
80,000
$10.4
80,000(Direct)
View


2016-12-31Disposition
2017-01-032:21 pm
N/AN/A
Avadel Pharmaceuticals Plc
AVDL
D'silva DhirenSee Remarks
15,000
$0
0(Direct)
View


2016-12-31Disposition
2017-01-032:21 pm
N/A2025-09-15
Avadel Pharmaceuticals Plc
AVDL
D'silva DhirenSee Remarks
50,000
$23.53
0(Direct)
View


2016-12-31Disposition
2017-01-032:21 pm
N/A2026-12-14
Avadel Pharmaceuticals Plc
AVDL
D'silva DhirenSee Remarks
80,000
$10.4
0(Direct)
View


2016-12-14Option Award
2016-12-169:38 pm
N/AN/A
Flamel Technologies Sa
FLML
D'silva DhirenSee Remarks
15,000
$0
80,000(Direct)
View


2016-12-14Option Award
2016-12-169:38 pm
N/A2026-12-14
Flamel Technologies Sa
FLML
D'silva DhirenSee Remarks
80,000
$10.4
80,000(Direct)
View


2016-12-14Option Award
2016-12-165:20 pm
N/AN/A
Flamel Technologies Sa
FLML
D'silva DhirenSee Remarks
18,000
$0
100,000(Direct)
View


2016-12-14Option Award
2016-12-165:20 pm
N/A2026-12-14
Flamel Technologies Sa
FLML
D'silva DhirenSee Remarks
100,000
$10.4
100,000(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 06:12:59 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  








      Dhiren D'silva - Insider Monkey                          Companies 0 See All     Hedge Funds 0 See All    Insiders 0 See All    Institutional Investors 0 See All   Click here to see all  results for  Sorry, no results has been found matching your query.                   Adblocker Detected    Dear Valued Visitor, We have noticed that you are using an ad blocker software.
    Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages. To view this article, you can disable your ad blocker and refresh this page or simply login. We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.       Home > Insider Trading > Dhiren D'silva
				> Profile    Dhiren D'silva    Profile Insider Purchases Insider Sales News      Affiliations  See Remarks at Avadel Pharmaceuticals Plc (AVDL), 2017-01-13                Home Hedge Funds Markets Blog Authors About Us Contact Us Privacy Policy Terms of Use Site Map  All text and design is copyright ©2016 Koala Guide LLC. All rights reserved.             


Dhiren A D'Silva - Somerset, NJ | Intelius



























Sign In



We found Dhiren A D'silva in Somerset, NJ


Dhiren A D'silva

                                                                           Intelius found that Dhiren A D'Silva  is  a male between 30 and 40 years old from Somerset, NJ.  We have connected them to
                6 addresses,
                2 phones,
                and 2 relatives or associates.
         





Also Known As

D  Silva


Get Report Now

Age

Dhiren A D'silva is in his 30s

Dhiren Has Lived In

Somerset, NJ
Bound Brook, NJ
North Brunswick, NJ

Dhiren's Relatives

Sunitha Dsilva
Alin D'Silva







Dhiren A D'silva



Zodiac SignLibra



GenderMale



Professional Status
Director, Business Development at Catalent Pharma Solutions Inc



Get Report Now










Want to know more about Dhiren? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Dhiren, or use our people search engine to find others.
Get Background Check on Dhiren A D'silva
Get a Criminal Check on Dhiren A D'silva
Get a Public Record Report on Dhiren A D'silva
Get a People Search Report on Dhiren A D'silva


Dhiren A D'silva's Contact Information
Known Cities Lived In
Find out where Dhiren A D'silva has lived as well as Dhiren A D'silva's phone numbers and email addresses.




Dhiren A D'silva Has Lived in 2 States
New Jersey Address for Dhiren A D'silva


204 V****** D* 

Somerset, NJ


Has Lived In

Somerset, NJ
Bound Brook, NJ


Get Full Address Report










Phone Numbers Associated with Dhiren A D'silva

(609) ***-**** - Somerset, NJ 
(732) ***-**** - North Brunswick, NJ 


Get Full Phone Report



Email Addresses Associated with Dhiren A D'silva



Get Email Report




Dhiren A D'silva's Education Information
Known Schools Attended
Learn about Dhiren A D'silva's academic history.  Find out which schools Dhiren A D'silva attended, the dates attended as well as the degrees Dhiren A D'silva received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Dhiren A D'silva Has Attended 1 School
Katholieke Universiteit Lewen 


Dhiren A D'silva's Professional Information
Information regarding Dhiren A D'silva's professional history.  Find out previous places Dhiren A D'silva has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Dhiren A D'silva Has Worked at 4 Places
Company: Catalent Pharma Solutions Inc
               Title: Director, Business Development
Company: Strides Arcolab Limited
               Title: Assistant General Manager
Dhiren A D'silva's Experience
Title: Director, Business Development
               Company: Catalent Pharma Solutions Inc
Job Details
               Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 9,200 people, including over 1,000 scientists, at more than 30 facilities across 5 continents and in fiscal 2016 generated $1.85 billion in annual revenue.
Title: Assistant General Manager
               Company: Strides Arcolab Limited
Job Details
               Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products. Strides has made significant investments in its own Biopharma venture, Stelis Biopharma, which will develop and manufacture selected recombinant proteins from the first wave of biosmilars as well as novel biologic therapies targeted against large and under-served treatment markets worldwide. The Company has 5 manufacturing facilities presence in more than 75 countries in developed and emerging markets.
Additional Professional Information on Dhiren A D'silva

 See Dhiren A D'silva's LinkedIn Profile



Dhiren A D'silva's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Dhiren A D'silva


Dhiren A D'silva's known Social Networks And Potential Email Matches

Find all of Dhiren A D'silva's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Dhiren D'Silva
Username Matches

                  DhirenD'Silva
                  D'SilvaDhiren
                  Dhiren.D'Silva
                  D'Silva.Dhiren
                  Dhiren_D'Silva
                  D'Silva_Dhiren
                  Dhiren-D'Silva
                  D'Silva-Dhiren
                  DD'Silva
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
D D'Silva







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.













Dhiren D'Silva, Avadel Pharmaceuticals PLC: Profile & Biography - Bloomberg


































































  
























Feedback





Dhiren D'Silva

VP:Irish & European Operations,
Avadel Pharmaceuticals PLC






Career History




VP:Irish & European Operations
Avadel Pharmaceuticals PLC, PRESENT


VP:Irish
Flamel Technologies SA, 9/2015-1/2017


Senior Dir:Intl Business Operations
Nps Pharmaceuticals Inc, 8/2013-9/2015


Dir:Business Development
Catalent Pharma Solutions, 1/2008-7/2013


Show More









Website:
www.avadel.com






Corporate Information
Address:

Block 10-1, Blanchardstown,
Corporate Park, Ballycoolin
Dublin 15
Ireland


Phone:
353-1-485-1200


Fax:
353-1-526-1077


Web url:
www.avadel.com











From The Web












Personal Information



Education



St Xavier's College
Bachelor's Degree, Economics








Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data

































Management | Avadel Pharmaceuticals





















Medical Professionals
Patients
Careers





Go













Home > About > Leadership



Leadership at Avadel Pharmaceuticals
Our management team is key to the success of our company. We are lead by
	 a diverse team of experts in their respective fields, each of whom help
	 to ensure the success of our business and ultimately the well-being of patients.




Michael S. Anderson, Chief Executive Officer

Michael S. Anderson has been Chief Executive Officer since March 2012.
Prior to Avadel, Mr. Anderson served in a number of leadership roles including CEO of Éclat Pharmaceuticals LLC, President and CEO of the generic business division of KV Pharmaceutical Company,  as well as President and CEO of Ther-RX Corporation, a leader in women's healthcare. Mr. Anderson started his career at A.H. Robins Company. 



Gregory J. Divis, EVP, Chief Commercial Officer

Gregory J. Divis was appointed Executive Vice President and Chief Commercial Officer in January of 2017. Prior to joining Avadel, he served as an Executive in Residence at Linden Capital Partners, a healthcare-focused private equity firm. With over 25 years of experience in the pharmaceutical industry, Mr. Divis served as President and Chief Executive Officer of Lumara Health, a specialty branded pharmaceutical company focused on women’s health. Prior to Lumara, Mr. Divis held general management, sales, marketing and business development roles at Schering Plough and Sanofi-Aventis.



Michael F. Kanan, SVP, Chief Financial Officer

Michael F. Kanan became Senior Vice President and Chief Financial Officer in October 2015. Prior to joining Avadel, Mr. Kanan was employed by Sigma-Aldrich Corp.
	 from April 2009 until November 2015, where he served as Vice President
	 Finance, Corporate Controller and Chief Accounting Officer of Sigma-Aldrich
	 from April 2009 until November 2015. Sigma-Aldrich is a life science and
	 high technology company which was acquired by Merck KGaA, a health care,
	 life science and performance materials company based in Germany, in November
	 2015. Mr. Kanan began his career at the international accounting firm
	 Deloitte & Touche, and also held accounting and finance leadership
	 positions with Hutchinson Group, a subsidiary of Total S.A., and Meritor,
	 a global supplier of drivetrain, mobility, braking and aftermarket solutions
	 for commercial vehicle and industrial markets.



Phillandas T. Thompson, SVP and General Counsel

Phil Thompson has been a Senior Vice President and General Counsel since November 2013. Prior to joining Avadel, Mr. Thompson worked in a variety of legal roles at companies such as West-Ward Pharmaceutical Corp. and Paddock Laboratories, Inc. where he served as Vice President, Legal Affairs and Vice President, General Counsel, respectively. He has also held the role of Vice President, Strategic Business Transactions and Assistant General Counsel at KV Pharmaceutical Co, and as Associate General Counsel at Barr Laboratories, Inc. Mr. Thompson is a member of the New York Bar, the Missouri Bar, and the Minnesota Bar.



Sandra L. Hatten, SVP, Quality and Regulatory Affairs

Sandra L. Hatten was appointed Senior Vice President of Quality and Regulatory
	 Affairs in June 2015. Prior to joining Avadel, Ms. Hatten was employed from October 2010 to June
	 2015 by Mallinckrodt, plc, a global specialty biopharmaceutical company,
	 where she served as Senior Vice President of Quality and Regulatory Compliance
	 from February 2014 until June 2015. From October 2010 until September
	 2012, Ms. Hatten was employed by Mallinckrodt, as Director and Sr. Director
	 of Quality. From September 2012 until February 2014, Ms. Hatten held the
	 position of Vice President, Quality and Regulatory Compliance with Mallinckrodt. Ms. Hatten has more than 30 years of experience in the pharmaceutical industry,
	 during which she has held leadership roles in quality and operations for
	 brand as well as generic drug manufacturers, where she has been responsible
	 for establishing and implementing broad-based quality programs across
	 multiple sites.



David Monteith, Ph.D., VP, Research and Development

David Monteith, Ph.D. was appointed Vice President of Research and Development
	 in October 2014. Prior to joining Avadel, Dr. Monteith was employed from 2009 to 2014 at
	 Merck & Co., Inc., a global healthcare solutions company, where he
	 held the position of Associate Vice President of Pharmaceutical Development
	 for Emerging Markets. From 2000 to 2009, Dr. Monteith was employed by
	 Schering-Plough Corporation, a pharmaceutical company that merged with
	 Merck & Co., Inc. in November 2009 in various positions from Associate
	 Director, Pharmaceutical Development to Senior Director, Product Value
	 Enhancement. With over 25 years of experience in the pharmaceutical industry, Dr. Monteith
	 has held senior leadership roles in the areas of drug delivery and pharmaceutical
	 drug product development.



Dhiren D’Silva, VP, Irish & European Operations

Dhiren D’Silva was appointed Vice President of Irish and European Operations in September 2015. Prior to joining Avadel, Mr. D’Silva was employed from August 2013
	 to September 2015 at NPS Pharmaceuticals Inc., a biopharmaceutical company
	 engaged in developing therapies for patients with rare diseases; NPS was
	 acquired by an affiliate of Shire plc in January 2015. Mr. D’Silva
	 held the position of Senior Director of International Business Operations
	 at NPS. Prior to his employment with NPS, Mr. D’Silva was employed
	 from January 2008 to July 2013 at Catalent Pharma Solutions Inc. a drug
	 delivery provider located in Somerset, New Jersey, as Director of Business
	 Development for its Product Ventures Group, focusing on the development
	 and out-licensing of ANDAs.






View Timeline


















DSILVA DHIREN Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      DSILVA DHIREN
                    

•   VENISSIEUX, I0
                      
How do I update this listing?




                                             Dsilva Dhiren is based out of Venissieux.   
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from DSILVA DHIREN, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




dsilva dhiren


33 AVENUE DU DR. GEORGES LEVY

VENISSIEUX
I0
                                                        
                                                    69200









Recent SEC Filings




4/A filed on 01/13/2017
4 filed on 01/03/2017
3 filed on 01/03/2017
4 filed on 01/03/2017
4/A filed on 12/16/2016
4 filed on 12/16/2016
3 filed on 01/04/2016
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free

















